AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10634401 — intervention group
Group type: COMPARATOR
Intervention: Calories, fat (animal or vegetable), and carbohydrate intake
Number of subjects: 1552
Study 9375433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercessory prayer
Number of subjects: 40
Study 9375433 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention (control)
Number of subjects: 40
Study 9375433 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who reported a family member or friend praying for them
Number of subjects: 40
Study 9375433 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater frequency of prayer by participants themselves
Number of subjects: 40
Study 1548391 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.6 mg/kg)
Number of subjects: 32
Study 1548391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 1548391 — intervention group
Group type: COMPARATOR
Intervention: Comparison boys (without ADHD)
Number of subjects: 32
Study 3981411 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat-action combination tablet containing 6 mg of dexbrompheniramine maleate with 120 mg of pseudoephedrine sulfate every 12 h for 7 d
Number of subjects: 12
Study 3981411 — intervention group
Group type: COMPARATOR
Intervention: Concomitant administration of conventional 2-mg dexbrompheniramine maleate tablets every 4 h and 120-mg pseudoephedrine sulfate repeat-action tablets every 12 h, each for 7 d
Number of subjects: 12
Study 30501447 — intervention group
Group type: EXPERIMENTAL
Intervention: Active condition (more than 15,000 steps per day)
Number of subjects: 16
Study 30501447 — intervention group
Group type: COMPARATOR
Intervention: Sedentary condition (less than 1,000 steps per day)
Number of subjects: 16
Study 30587944 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy (LH)
Number of subjects: 116
Study 27589059 — intervention group
Group type: EXPERIMENTAL
Intervention: MD1003 (100 mg biotin)
Number of subjects: 154
Study 27589059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 24583567 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/day
Number of subjects: 427
Study 24583567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 427
Study 22348492 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mg/kg oral erythromycin every 6 hours for 14 days (n=19)
Number of subjects: 45
Study 22348492 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=26)
Number of subjects: 45
Study 19136327 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention to reduce severity of oral mucositis and oral pain
Number of subjects: 0
Study 19136327 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 17964463 — intervention group
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 15
Study 15007512 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 140
Study 15007512 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) + Creatine
Number of subjects: 140
Study 12363116 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy plus paroxetine (40 mg/day)
Number of subjects: 161
Study 12363116 — intervention group
Group type: COMPARATOR
Intervention: Cognitive‐behavioral therapy plus placebo
Number of subjects: 161
Study 9672949 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention
Number of subjects: 90
Study 9672949 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 90
Study 9672949 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline smoking prevalence
Number of subjects: 90
Study 9672949 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up smoking cessation rates
Number of subjects: 90
Study 7721239 — intervention group
Group type: EXPERIMENTAL
Intervention: Granular (G) type duodenitis
Number of subjects: 117
Study 7721239 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi‐polypoid (MP) type duodenitis
Number of subjects: 117
Study 7721239 — intervention group
Group type: EXPERIMENTAL
Intervention: Reddened (R) type duodenitis
Number of subjects: 117
Study 7721239 — intervention group
Group type: EXPERIMENTAL
Intervention: Erosive (E) type duodenitis
Number of subjects: 117
Study 7721239 — intervention group
Group type: COMPARATOR
Intervention: Histological analysis of duodenitis specimens
Number of subjects: 117
Study 2481775 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine-ER 10 mg
Number of subjects: 109
Study 2481775 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine-ER 20 mg
Number of subjects: 109
Study 2481775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 1234484 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (single oral dose)
Number of subjects: 0
Study 1234484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31727391 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led multidisciplinary self-management program (NMSP)
Number of subjects: 144
Study 31727391 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 144
Study 31094122 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Permethrin
Number of subjects: 160
Study 31094122 — intervention group
Group type: COMPARATOR
Intervention: 10% Crotamiton
Number of subjects: 160
Study 27177182 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical rehearsal platform (SRP)
Number of subjects: 25
Study 27177182 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SRP)
Number of subjects: 25
Study 26683695 — intervention group
Group type: EXPERIMENTAL
Intervention: HOLA intervention
Number of subjects: 60
Study 26683695 — intervention group
Group type: COMPARATOR
Intervention: Fotonovela (control)
Number of subjects: 60
Study 23193217 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop basal insulin delivery
Number of subjects: 12
Study 23193217 — intervention group
Group type: COMPARATOR
Intervention: Conventional pump therapy
Number of subjects: 12
Study 21632228 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 0.4 mg
Number of subjects: 81
Study 21632228 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 81
Study 17566124 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (maximum dose 30 mg/kg/day)
Number of subjects: 22
Study 17566124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15022802 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction drainage (CSD)
Number of subjects: 104
Study 15022802 — intervention group
Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 104
Study 12116023 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg daily
Number of subjects: 100
Study 12116023 — intervention group
Group type: COMPARATOR
Intervention: Famciclovir 500 mg three times a day
Number of subjects: 100
Study 9537221 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg azimilide orally each day
Number of subjects: 3
Study 9537221 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg azimilide orally each day
Number of subjects: 3
Study 9537221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 7711992 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (HbA1c < 7%)
Number of subjects: 1441
Study 7711992 — intervention group
Group type: COMPARATOR
Intervention: Conventional glycemic control (HbA1c > 9%)
Number of subjects: 1441
Study 2675895 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA; 2 mg/kg per day) in combination with CyA (group AZA+)
Number of subjects: 78
Study 2675895 — intervention group
Group type: COMPARATOR
Intervention: CyA alone (group AZA‐)
Number of subjects: 78
Study 593193 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic preparation with a sequence of 6/5/10
Number of subjects: 10
Study 593193 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic preparation with a reduced content of total dose of oestrogen per cycle
Number of subjects: 10
Study 31062517 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate functional loading (screw‐retained or cemented single or splinted restorations in full occlusal contact)
Number of subjects: 20
Study 31062517 — intervention group
Group type: COMPARATOR
Intervention: Immediate nonfunctional loading (screw‐retained or cemented single or splinted restorations in infraocclusion)
Number of subjects: 20
Study 31062517 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction assessment using a questionnaire with visual analog scales
Number of subjects: 20
Study 28444950 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position for 5 hours without PFCO
Number of subjects: 56
Study 28444950 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position for 5 hours without PFCO
Number of subjects: 56
Study 28444950 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position for 5 hours with PFCO
Number of subjects: 56
Study 28444950 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position for 5 hours with PFCO
Number of subjects: 56
Study 25870057 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐663068 at 600 mg BID
Number of subjects: 36
Study 25870057 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐663068 at 600 mg BID plus RTV at 100 mg QD
Number of subjects: 36
Study 25870057 — intervention group
Group type: COMPARATOR
Intervention: ATV/r (ATV at 300 mg QD plus RTV at 100 mg QD)
Number of subjects: 36
Study 25870057 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐663068 at 600 mg BID plus ATV at 300 mg QD plus RTV at 100 mg QD
Number of subjects: 36
Study 24579286 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum containing tea polyphenol
Number of subjects: 157
Study 24579286 — intervention group
Group type: COMPARATOR
Intervention: Chewing gum without tea polyphenol (control gum)
Number of subjects: 157
Study 24579286 — intervention group
Group type: COMPARATOR
Intervention: No chewing gum (no gum group)
Number of subjects: 157
Study 21477057 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol commercials
Number of subjects: 184
Study 21477057 — intervention group
Group type: COMPARATOR
Intervention: Nonalcohol commercials
Number of subjects: 184
Study 19061743 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of 10% of body mass in weight belt
Number of subjects: 84
Study 19061743 — intervention group
Group type: COMPARATOR
Intervention: No weight belt (control)
Number of subjects: 84
Study 15858159 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Hz (16-24 Hz) activity suppression during mouth movements
Number of subjects: 0
Study 15858159 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-related change in 20 Hz activity
Number of subjects: 0
Study 15858159 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-speech movements
Number of subjects: 0
Study 15635512 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 44
Study 15635512 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 44
Study 15635512 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled interscalene analgesia with 0.15% bupivacaine
Number of subjects: 44
Study 15635512 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled interscalene analgesia with 0.15% ropivacaine
Number of subjects: 44
Study 15635512 — intervention group
Group type: COMPARATOR
Intervention: Both groups (bupivacaine and ropivacaine)
Number of subjects: 44
Study 12056469 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissucol
Number of subjects: 56
Study 10179922 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac/misoprostol (Arthrotec®)
Number of subjects: 0
Study 10179922 — intervention group
Group type: COMPARATOR
Intervention: NSAID therapy (not specified)
Number of subjects: 0
Study 10179922 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroprotective NSAIDs
Number of subjects: 0
Study 7917153 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Ser-Tyr28 ANH (0.6 pmol/kg/min) infusion during low-salt diet (LS+ANH)
Number of subjects: 8
Study 7917153 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion during low-salt diet (LS)
Number of subjects: 8
Study 7917153 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion during high-salt diet (HS)
Number of subjects: 8
Study 2576363 — intervention group
Group type: EXPERIMENTAL
Intervention: picumast dihydrochloride 1 mg
Number of subjects: 99
Study 2576363 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine 60 mg
Number of subjects: 99
Study 2576363 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 99
Study 765435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloward procedure (anterior approach)
Number of subjects: 51
Study 765435 — intervention group
Group type: COMPARATOR
Intervention: Radical discectomy and foraminotomy
Number of subjects: 51
Study 31789554 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic beverage (target BrAC = .08 g%)
Number of subjects: 145
Study 31789554 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 145
Study 30496426 — intervention group
Group type: EXPERIMENTAL
Intervention: Good value estimation methodology (total cholesterol of 170 mg/dl and HDL‐cholesterol of 50 mg/dl)
Number of subjects: 345440
Study 30496426 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal imputation methodology
Number of subjects: 345440
Study 27013221 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance Commitment Therapy (ACT) intervention; 6 sessions
Number of subjects: 31
Study 27013221 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 31
Study 26606003 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume injectate (8 mL)
Number of subjects: 66
Study 26606003 — intervention group
Group type: COMPARATOR
Intervention: Low-volume injectate (3 mL)
Number of subjects: 66
Study 26606003 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study 23368828 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg of body mass/day)
Number of subjects: 30
Study 23368828 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 30
Study 22364063 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention program
Number of subjects: 108
Study 22364063 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108
Study 19889067 — intervention group
Group type: EXPERIMENTAL
Intervention: EAC (esomeprazole 20 mg b.d., amoxycillin 1 g b.d., and clarithromycin 500 mg b.d.)
Number of subjects: 300
Study 19889067 — intervention group
Group type: COMPARATOR
Intervention: EAL (esomeprazole 20 mg b.d., amoxycillin 1 g b.d., and levofloxacin 500 mg daily)
Number of subjects: 300
Study 19889067 — intervention group
Group type: EXPERIMENTAL
Intervention: EAC
Number of subjects: 300
Study 19889067 — intervention group
Group type: COMPARATOR
Intervention: EAL
Number of subjects: 300
Study 17230483 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral deep brain stimulation of the subthalamic nucleus (STN)
Number of subjects: 33
Study 17230483 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral deep brain stimulation of the globus pallidus internus (GPi)
Number of subjects: 33
Study 17230483 — intervention group
Group type: COMPARATOR
Intervention: Unilateral deep brain stimulation of either STN or GPi
Number of subjects: 33
Study 17230483 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative medication responsiveness
Number of subjects: 33
Study 14764786 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment with dosages of 1 mg/m².d and 2 mg/m².d (approximately 0.035 and 0.070 mg/kg.d, respectively) for 1 year
Number of subjects: 351
Study 14764786 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal-statured children born appropriate for gestational age)
Number of subjects: 351
Study 11905723 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of randomised clinical trials in oncology
Number of subjects: 0
Study 11905723 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis using individual patient data
Number of subjects: 0
Study 11905723 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of individual patient data
Number of subjects: 0
Study 8997462 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antimicrobial gels containing 4 times minimally inhibitory in vitro concentrations
Number of subjects: 0
Study 8997462 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antimicrobial gels containing 8 times minimally inhibitory in vitro concentrations
Number of subjects: 0
Study 8997462 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 0
Study 8203854 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam (6 g/day [2 g intravenously every 8 h] for 10 days)
Number of subjects: 44
Study 8203854 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol (50 mg/kg of body weight per day [intravenously or orally] for 14 days)
Number of subjects: 44
Study 3555596 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA with oral 8‐methoxypsoralen (8‐MOP)
Number of subjects: 42
Study 3555596 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB with oral placebo
Number of subjects: 42
Study 3555596 — intervention group
Group type: COMPARATOR
Intervention: Control low‐dose UVA with oral placebo
Number of subjects: 42
Study 30865022 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound treatment
Number of subjects: 57
Study 30865022 — intervention group
Group type: COMPARATOR
Intervention: Baseline stiffness
Number of subjects: 57
Study 30865022 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in stiffness
Number of subjects: 57
Study 27903827 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure applied to seven auricular acupoints for 6 weeks using vaccaria seeds
Number of subjects: 52
Study 27084116 — intervention group
Group type: EXPERIMENTAL
Intervention: SASA! community mobilisation intervention
Number of subjects: 1583
Study 24562804 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 2995
Study 24562804 — intervention group
Group type: COMPARATOR
Intervention: Control (no tirofiban)
Number of subjects: 2995
Study 22309432 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion
Number of subjects: 72
Study 22309432 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate infusion (control)
Number of subjects: 72
Study 20643194 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (6 mg)
Number of subjects: 24
Study 17549324 — intervention group
Group type: EXPERIMENTAL
Intervention: ICF Brief Core Set
Number of subjects: 402
Study 17549324 — intervention group
Group type: EXPERIMENTAL
Intervention: ICF Comprehensive Core Set
Number of subjects: 402
Study 17549324 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-rater agreement
Number of subjects: 402
Study 17549324 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of codes d920 and d650
Number of subjects: 402
Study 16172545 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (50 mg once daily)
Number of subjects: 45
Study 16172545 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg once daily)
Number of subjects: 45
Study 16172545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 12163662 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean isoflavone glycosides
Number of subjects: 14
Study 12163662 — intervention group
Group type: EXPERIMENTAL
Intervention: Red clover isoflavone aglycones
Number of subjects: 14
Study 12163662 — intervention group
Group type: COMPARATOR
Intervention: Control (washout period)
Number of subjects: 14
Study 9790130 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 192
Study 9790130 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 192
Study 9097762 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC)
Number of subjects: 39
Study 9097762 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 39
Study 2692764 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 2692764 — intervention group
Group type: COMPARATOR
Intervention: Moclobemide
Number of subjects: 0
Study 345632 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglumine iodamide (0.8 cc/kg to a maximum of 55 cc)
Number of subjects: 50
Study 345632 — intervention group
Group type: COMPARATOR
Intervention: Renografin 60 (52% meglumine diatrizoate and 8% sodium diatrizoate) (0.8 cc/kg to a maximum of 55 cc)
Number of subjects: 50
Study 31538976 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery audio file for 20 minutes per day for one week
Number of subjects: 0
Study 31538976 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29282115 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified transvaginal mesh surgery (mTVM group, n = 65)
Number of subjects: 130
Study 29282115 — intervention group
Group type: COMPARATOR
Intervention: Original transvaginal mesh surgery (TVM group, n = 65)
Number of subjects: 130
Study 29282115 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (mTVM and TVM)
Number of subjects: 130
Study 25722067 — intervention group
Group type: EXPERIMENTAL
Intervention: LEDT at 210 J (40 s)
Number of subjects: 12
Study 25722067 — intervention group
Group type: EXPERIMENTAL
Intervention: LEDT at 315 J (60 s)
Number of subjects: 12
Study 25722067 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 J)
Number of subjects: 12
Study 25722067 — intervention group
Group type: EXPERIMENTAL
Intervention: LEDT at 105 J (20 s)
Number of subjects: 12
Study 24322420 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of ATP injected before PVI in AF patients
Number of subjects: 125
Study 24322420 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of ATP injected in AVRT patients
Number of subjects: 125
Study 24322420 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP-induced AF
Number of subjects: 125
Study 24322420 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous AF
Number of subjects: 125